15 March 2018
Dechra® Pharmaceuticals PLC
(Dechra or the Company)
Additional Listing
An application has been made to the Financial Conduct Authority and the London Stock Exchange for a total of 70,000 ordinary shares of 1 pence each (the "Shares") to be admitted to the Official List.
These Shares are being reserved under a block listing and will be issued pursuant to the following scheme:
Scheme |
Shares |
Save As You Earn (SAYE) |
14,000 |
Long Term Incentive Plan (LTIP) |
56,000 |
These Shares will rank pari passu with the Company's existing shares in issue. It is expected that admission will become effective on 21 March 2018.
For further information
For further information, please contact:
Dechra Pharmaceuticals PLC
Melanie Hall, Company Secretary
Telephone number: +44 (0) 1606 814730
Email: corporate.enquiries@dechra.com
About Dechra
Dechra is an international specialist veterinary pharmaceuticals and related products business. Our expertise is in the development, manufacture, and sales and marketing of high quality products exclusively for veterinarians worldwide. The majority of Dechra's products are focused on key therapeutic categories where we have leading market positions, and many of our products are used to treat medical conditions for which there is no other effective solution or have a clinical or dosing advantage over competitor products. For more information, please visit: www.dechra.com.
Trademarks
Trademarks appear throughout this document in italics. Dechra and the Dechra "D" logo are registered trademarks of Dechra Pharmaceuticals PLC.